Abstract
Purpose: We developed and evaluated a GM-CSF whole-cell tumor vaccine for esophageal cancer. Experimental design: Cell lines derived from surgically induced rat reflux esophageal tumors were passaged in vitro and transfected with GM-CSF. First, the GM-CSF whole cell vaccine was evaluated against subcutaneously transplanted esophageal tumor cells. In a subsequent study, the vaccine was tested to see if it could reduce the incidence of cancer in the surgical reflux model. Results: While subcutaneously transplanted tumor cells produced lasting tumors in PBS non-vaccinated placebo rats, transplanted tumors regressed and were immunologically rejected in animals vaccinated prior to implantation. In the surgical reflux model, the vaccine reduced the incidence of cancer from 17/23 (74%) in the controls to 6/16 (38%) in the vaccinated animals (P = 0.046). Conclusions: The GM-CSF whole cell tumor vaccine effectively promoted a strong immune response against subcutaneously transplanted tumors and protected animals from developing esophageal cancer in the reflux model.
Original language | English (US) |
---|---|
Pages (from-to) | 2858-2867 |
Number of pages | 10 |
Journal | Digestive diseases and sciences |
Volume | 53 |
Issue number | 11 |
DOIs | |
State | Published - Nov 2008 |
Keywords
- Barrett's esophagus
- Esophageal cancer
- GM-CSF
- Vaccine
ASJC Scopus subject areas
- Physiology
- Gastroenterology